Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study.

Javier Trujillo-SantosDominique Farge-BancelJosé María PedrajasCovadonga Gómez-CuervoAitor BallazAndrei BraesterIsabelle MahéAurora VillalobosJosé Antonio PorrasManuel Monrealnull null

Published in: Research and practice in thrombosis and haemostasis (2022)

In RIETECAT, in patients with cancer and VTE receiving full-dose enoxaparin or dalteparin or tinzaparin, no statistically significant differences were observed regarding effectiveness and safety outcomes over a 6-month period.

Keyphrases

venous thromboembolism
direct oral anticoagulants
type diabetes
adipose tissue
skeletal muscle
glycemic control